2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other
2
Classical hematology
2
Conditions
Multiple Myeloma
5
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Cytokine Release Syndrome
2
Burkitt Lymphoma
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Smoldering Multiple Myeloma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Meropenem
7
Vancomycin
6
pegfilgrastim
5
Filgrastim
5
Ceftazidime
5
pegylated granulocyte colony-stimulating factor
4
Cefepime
4
Levofloxacin
3
Ciprofloxacin
3
Amikacin
3
Teicoplanin
2
Piperacillin, Tazobactam Drug Combination
2
Linezolid
2
Interleukin 1 Receptor Antagonist Protein
2
Anti-Bacterial Agents
2
Amoxicillin-Potassium Clavulanate Combination
2
ceftolozane, tazobactam drug combination
1
Vaccination
1
Therapeutics
1
Tazobactam
1
TKN732
1
Surveys and Questionnaires
1
Sodium Chloride
1
Simvastatin
1
Positron Emission Tomography Computed Tomography
1
Pneumococcal Vaccines
1
Piperacillin
1
Ofloxacin
1
NF protocol
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Febrile Neutropenia
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT03233776
2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2
Completed
9 enrolled
NCT04099901
2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2
Completed
88 enrolled